The PCA from the gene expression data on combined DCISs of all HER2-positive patients showed that the patient explains the major difference in the transcriptomic profiles (Supplementary Figure 6), which implies the underlying heterogeneity of HER2-positive breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.